Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
16
02
2023
accepted:
28
03
2023
revised:
27
03
2023
medline:
10
7
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
We compared transplants (HSCT) from matched related siblings (MSD) with those from matched 10/10 and mismatched 9/10 unrelated (UD) and T-replete haploidentical (Haplo) donors in acute myeloid leukemia (AML) in first complete remission (CR1) achieved after two inductions, a known poor prognostic factor. One thousand two hundred and ninety-five patients were included: MSD (n = 428), UD 10/10 (n = 554), UD 9/10 (n = 135), and Haplo (n = 178). Acute GVHD II-IV was higher in all groups compared to MSD. Extensive chronic (c) GVHD was significantly higher in UD 9/10 (HR = 2.52; 95% CI 1.55-4.11, p = 0.0002) and UD 10/10 (HR = 1.48; 95% CI 1.03-2.13, p = 0.036) and cGVHD all grades were higher in UD 9/10 vs MSD (HR = 1.77; 95% CI 1.26-2.49, p = 0.0009). Non-relapse mortality was higher in all groups compared to MSD. Relapse incidence, leukemia-free, and overall survival did not differ significantly between donor types. Finally, GVHD-free relapse-free survival was lower in HSCT from UD 9/10 (HR = 1.56, 95% CI 1.20-2.03, p = 0.0009) but not in those from UD 10/10 (HR = 1.13, p = 0.22) and Haplo donors (HR = 1.12, p = 0.43) compared to MSD. In conclusion, in AML patients undergoing HSCT in CR1 achieved after two induction courses 10/10 UD and Haplo but not 9/10 UD donors are comparable alternatives to MSD.
Identifiants
pubmed: 37045942
doi: 10.1038/s41409-023-01980-y
pii: 10.1038/s41409-023-01980-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
791-800Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.
pubmed: 26376137
doi: 10.1056/NEJMra1406184
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:6–20.
pubmed: 32966881
doi: 10.1016/j.bbmt.2020.09.020
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8:e205–15.
pubmed: 33636142
pmcid: 9190021
doi: 10.1016/S2352-3026(20)30394-X
Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F. et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol. 2015;33:3144–51.
pubmed: 26240227
doi: 10.1200/JCO.2014.59.1339
Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3:1881–90.
pubmed: 31221661
pmcid: 6595255
doi: 10.1182/bloodadvances.2019032268
Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. Clin Cancer Res. 2022;28:4258–66. clincanres.0809.2022-3-14 14:38:43.713.
Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31:1293–301.
pubmed: 23439754
doi: 10.1200/JCO.2011.40.5977
Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34:87–99.
pubmed: 31363160
doi: 10.1038/s41375-019-0527-4
Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56:218–24.
pubmed: 32724200
doi: 10.1038/s41409-020-01005-y
Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142–52.
pubmed: 29981272
doi: 10.1002/ajh.25211
Sharvit G, Heering G, Zlotnik M, Merkel D, Nagler A, Avigdor A, et al. Acute myeloid leukemia patients requiring two cycles of intensive induction for attainment of remission experience inferior survival compared with patients requiring a single course of induction chemotherapy. Clin Lymphoma Myeloma Leuk. 2022;22:e116–23.
pubmed: 34593360
doi: 10.1016/j.clml.2021.08.014
Nagler A, Labopin M, Huang XJ, Blaise D, Arcese W, Araujo MC, et al. Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2022;57:572–8.
pubmed: 35105964
doi: 10.1038/s41409-021-01537-x
Nagler A, Galimard JE, Labopin M, Blaise D, Arcese W, Trisolini SM. et al. Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: a study from the ALWP of the EBMT. Cancer Med. 2023;12:1482–91. https://doi.org/10.1002/cam4.5039 .
doi: 10.1002/cam4.5039
pubmed: 35891608
Walter RB, Sandmaier BM, Storer BE, Buckley SA, Pagel JM, Sorror ML, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant. 2015;21:373–8.
pubmed: 25278455
doi: 10.1016/j.bbmt.2014.09.022
Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196–207.
pubmed: 32871588
doi: 10.1182/blood.2020005514
Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood. 2009;113:2851–8.
pubmed: 18997170
doi: 10.1182/blood-2008-08-171934
Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S, et al. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant. 2009;44:571–7.
pubmed: 19363528
doi: 10.1038/bmt.2009.67
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
pubmed: 19896087
pmcid: 2861656
doi: 10.1016/j.bbmt.2009.07.004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinic pathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.
pubmed: 6996481
doi: 10.1016/0002-9343(80)90380-0
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–1.
pubmed: 26657834
doi: 10.1038/bmt.2015.305
Abraham SK, Arnon N, Bipin S. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.
doi: 10.2991/chi.d.191207.001
Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500.
pubmed: 10398287
doi: 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. https://www.R-project.org/ .
Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20:1975–81.
pubmed: 25263628
pmcid: 4343203
doi: 10.1016/j.bbmt.2014.08.013
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40.
pubmed: 26130705
pmcid: 4543223
doi: 10.1182/blood-2015-04-639831
Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10:24.
pubmed: 28103944
pmcid: 5248464
doi: 10.1186/s13045-017-0394-2
Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;6:13. 46
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55.
pubmed: 29661208
pmcid: 5902953
doi: 10.1186/s13045-018-0598-0
Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multi center cohort study. Leukemia. 2020;34:1433–43.
pubmed: 31831845
doi: 10.1038/s41375-019-0686-3
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9:89.
pubmed: 27639553
pmcid: 5027089
doi: 10.1186/s13045-016-0321-y
Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH. et al. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol. 2021;18:1172–85.
pubmed: 33408344
pmcid: 8093297
doi: 10.1038/s41423-020-00597-1
Lu Y, Zhao YL, Zhang JP, Xiong M, Cao XY, Liu DY, et al. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Ann Hematol. 2020;99:2911–25.
pubmed: 33000361
doi: 10.1007/s00277-020-04283-0
Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34:1433–43.
pubmed: 31831845
doi: 10.1038/s41375-019-0686-3
Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17:821–30.
pubmed: 20831895
doi: 10.1016/j.bbmt.2010.08.023
Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134.
pubmed: 28676064
pmcid: 5496245
doi: 10.1186/s13045-017-0502-3
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892–9.
pubmed: 31270102
doi: 10.1182/blood.2019000487
Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–84.
pubmed: 31477550
doi: 10.1016/S2352-3026(19)30158-9
Loke J, Labopin M, Craddock C, Niederwieser D, Cornelissen J, Afansayev B, et al. Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. Bone Marrow Transplant. 2021;56:614–21.
pubmed: 33009514
doi: 10.1038/s41409-020-01072-1
Nagler A, Dholaria B, Labopin M, Bruno B, Rambaldi A, Pioltelli P, et al. The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. Bone Marrow Transplant. 2021;56:20–29.
pubmed: 32561816
doi: 10.1038/s41409-020-0974-6
Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, et al. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. J Hematol Oncol. 2016;9:65.
pubmed: 27488518
pmcid: 4971653
doi: 10.1186/s13045-016-0295-9
Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–52.
pubmed: 30846862
doi: 10.1038/s41375-019-0439-3
Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: a study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2021;10:23–33.
pubmed: 33242374
doi: 10.1002/cam4.3593
Ringden O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25:1975–83.
pubmed: 31181255
doi: 10.1016/j.bbmt.2019.05.037
Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, et al. The impact of anti-thymocyte globulin on the outcomes of patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia. 2020;34:1144–53.
pubmed: 31728052
doi: 10.1038/s41375-019-0631-5
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.
pubmed: 28380315
pmcid: 5455603
doi: 10.1200/JCO.2016.70.7091
Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9:118.
pubmed: 27821187
pmcid: 5100212
doi: 10.1186/s13045-016-0347-1
Qayed M, Watkins B, Gillespie S, Bratrude B, Betz K, Choi SW, et al. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2022;6:746–9.
pubmed: 34753172
pmcid: 8945296
doi: 10.1182/bloodadvances.2021005208
Sourisseau M, Faure E, Béhal H, Chauvet P, Srour M, Capes A, et al. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Adv. 2023;7:856–65.
pubmed: 36350752
doi: 10.1182/bloodadvances.2022008667